GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cidara Therapeutics Inc (FRA:20D0) » Definitions » Net Margin %

Cidara Therapeutics (FRA:20D0) Net Margin % : 0.00% (As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Cidara Therapeutics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Cidara Therapeutics's Net Income for the three months ended in Dec. 2024 was €-49.95 Mil. Cidara Therapeutics's Revenue for the three months ended in Dec. 2024 was €0.00 Mil. Therefore, Cidara Therapeutics's net margin for the quarter that ended in Dec. 2024 was 0.00%.

The historical rank and industry rank for Cidara Therapeutics's Net Margin % or its related term are showing as below:

FRA:20D0' s Net Margin % Range Over the Past 10 Years
Min: -13319.76   Med: -147.48   Max: -52.11
Current: -1937.56


FRA:20D0's Net Margin % is ranked worse than
80.62% of 1001 companies
in the Biotechnology industry
Industry Median: -126.37 vs FRA:20D0: -1937.56

Cidara Therapeutics Net Margin % Historical Data

The historical data trend for Cidara Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cidara Therapeutics Net Margin % Chart

Cidara Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -597.59 -85.67 -52.11 -98.49 -13,315.68

Cidara Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -116.58 -122.01 -30,154.09 - -

Competitive Comparison of Cidara Therapeutics's Net Margin %

For the Biotechnology subindustry, Cidara Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cidara Therapeutics's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cidara Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Cidara Therapeutics's Net Margin % falls into.


;
;

Cidara Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Cidara Therapeutics's Net Margin for the fiscal year that ended in Dec. 2024 is calculated as

Net Margin=Net Income (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-162.185/1.218
=-13,315.68 %

Cidara Therapeutics's Net Margin for the quarter that ended in Dec. 2024 is calculated as

Net Margin=Net Income (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-49.953/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cidara Therapeutics  (FRA:20D0) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Cidara Therapeutics Net Margin % Related Terms

Thank you for viewing the detailed overview of Cidara Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cidara Therapeutics Business Description

Traded in Other Exchanges
Address
6310 Nancy Ridge Drive, Suite 101, San Diego, CA, USA, 92121
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.

Cidara Therapeutics Headlines

No Headlines